Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pozen has notified the FDA that ownership of the investigational new drug application and new drug application for Treximet has been officially transferred to GlaxoSmithKline.
Subscribe to our email newsletter
The FDA approved Treximet for the acute treatment of migraine attacks, with or without aura, in adults on April 15, 2008. Treximet will be commercialized by GlaxoSmithKline.